Released May 7, 2026, after the close
10-Q filed May 7, 2026, 37 days after period end · 0001628280-26-032293
Q1 2026 · 10-Q
Revenue$44.14M$44.14M +6.5% vs Q1 2025−29.0% vs Q4 2025
Net Income-$18.87M-$18.87M N/M vs Q1 2025N/M vs Q4 2025
EPS Diluted-$0.15-$0.15 N/M vs Q1 2025no prior Q4 2025 on file
Gross Profit$21,254,000+5.4%
Operating Income-$18,463,000N/M
Operating Cash Flow-$2,736,000N/M
Free Cash Flowderived-$4,904,000N/M
Margins · derived
Gross margin48.2%−0.5 pt vs Q1 2025
Operating margin-41.8%−5.7 pt vs Q1 2025
Net margin-42.7%−15.2 pt vs Q1 2025
What the release said
The release
Same quarter
| Metric | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 |
|---|---|---|---|---|
| Revenue | $44.14M | $41.46M | $44.86M | $37.09M |
| Net Income | -$18.87M | -$11.40M | -$6.17M | -$6.81M |
| EPS Diluted | -$0.15 | -$0.09 | -$0.05 | -$0.05 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Cytek Biosciences, Inc. · CIK 1831915 · Engraved from SEC EDGAR